COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Lidocaine and Neuroma Pain Related Modalities

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02300038
Recruitment Status : Completed
First Posted : November 24, 2014
Last Update Posted : November 24, 2014
Information provided by (Responsible Party):
Adriana Miclescu, Uppsala University

Brief Summary:

Background Subanesthetics concentrations of lidocaine are able to produce a differential block of the ectopic discharges, but not propagation of impulses, suppressing differentially the associated neuropathic pain symptoms. The aim of this study was to investigate the differences between the analgesic effects of lidocaine 0.5% and a control group of lidocaine 0.1% on several neuroma related pain modalities.

Methods Sixteen patients with neuropathic pain due to painful neuromas caused by nerve injury participated in this randomized, double-blind experiment. The patterns of sensory changes were compared before and after injection of 1 ml lidocaine 0.5% and 0.1% close to the neuroma, the sessions being 1-2 weeks apart. Spontaneous and evoked pains were assessed using a visual analogue scale (VAS), quantitative and qualitative sensory testing.

Condition or disease Intervention/treatment Phase
Neuropathic Pain Drug: Lidocaine (Xylocaine) Dietary Supplement: NaCl Not Applicable

Detailed Description:

Patients were recruited by using a postal follow up questionnaire . The number of enrolled subjects in this study- 16 patients, Study design

  • The patients visited the Pain Clinic twice.
  • The same investigator (AM) performed all study procedure assessments.
  • Neuroma was localized by Tinel`s sign 14 and when possible (7 patients out of 16), the localization of a neuroma was verified by ultrasound.

Administration of study drug The patients were randomized by a computer generated random list to receive either 1ml lidocaine 0.5% (A) or 1 ml 0.1% (B-control) injected perineuromally.

Pain assessments Duration of the present pain condition was recorded. The patients were asked to rate the mean, maximum, minimum pain intensity of their spontaneous and evoked pain in the week prior to both visits. The pain score was measured from baseline until 60 min after injection. Assessments of pain were done post injection at 15 s, 30 s, 1 min, and at 5-min intervals for the first 30-min post injection and then every 10-min to 1 hr post injection. The assessments of pain were performed between the limbs in the following order: spontaneous pain, then assessment of dynamic mechanical allodynia and then pinprick hyperalgesia.

Spontaneous pain Evaluation of sensory function was performed in the affected limb using bedside examination according to EFNS (European Federation of Neurological Societies)guidelines: light touch, pinprick sense, warmth (40°) and cold (25°) temperature stimuli were tested.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 16 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Investigator)
Official Title: Differential Analgesic Effects of Subanesthetic Concentrations of Lidocaine on Spontaneous and Evoked Pain in Human Painful Neuroma
Study Start Date : April 2010
Actual Primary Completion Date : August 2013
Actual Study Completion Date : September 2014

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Active Comparator: Lidocaine (Xylocaine) 0.5%
Injection of 1ml after mixing Lidocaine 10 mg/ml 1 ml +1 ml NaCl was administrated perineuromally
Drug: Lidocaine (Xylocaine)
perineuromally administration of 1 ml lidocaine
Other Names:
  • Xylocaine
  • Lidocaine

Dietary Supplement: NaCl
perineuromally administration of NaCL
Other Names:
  • Sodium chloride
  • salt

Placebo Comparator: Lidocaine (Xylocaine) 10 mg/ml 0.01%
Injection of 1 ml from 10 mg/ml 1 ml lidocaine Xylocaine +10 ml Nacl was adminsitrated perineuromally
Drug: Lidocaine (Xylocaine)
perineuromally administration of 1 ml lidocaine
Other Names:
  • Xylocaine
  • Lidocaine

Dietary Supplement: NaCl
perineuromally administration of NaCL
Other Names:
  • Sodium chloride
  • salt

Primary Outcome Measures :
  1. The primary end-point measure was defined as the change in pain score measured from baseline until 60 min after injection [ Time Frame: 60 min ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • 18 years or older,
  • with a history of persistent spontaneous and/or evoked pain (by e.g. touch, movement),
  • who scored an average daily pain intensity of at least 4 on a 0-10 point numerical pain scale (NRS) interfering with daily activities and who had pain at least 3 months duration.
  • They all had neuromas after upper extremity surgery or other trauma affecting the radial, ulnar, median or digital nerves and were eligible to participate in the study after giving written informed consent.

Exclusion Criteria:

  • Patients with other conditions that might confound assessment of pain attributed to posttraumatic upper limb pain or
  • any condition/disease that could interfere with the study measurements, such as drug abuse, diabetes, vascular disease, polyneuropathy or psychiatric diseases were excluded.

Layout table for additonal information
Responsible Party: Adriana Miclescu, MD, PhD, DEAA, Uppsala University Identifier: NCT02300038    
Other Study ID Numbers: UppsalaU
First Posted: November 24, 2014    Key Record Dates
Last Update Posted: November 24, 2014
Last Verified: November 2014
Additional relevant MeSH terms:
Layout table for MeSH terms
Peripheral Nervous System Diseases
Neuromuscular Diseases
Nervous System Diseases
Neurologic Manifestations
Signs and Symptoms
Nerve Sheath Neoplasms
Neoplasms, Nerve Tissue
Neoplasms by Histologic Type
Anesthetics, Local
Central Nervous System Depressants
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents
Anti-Arrhythmia Agents
Voltage-Gated Sodium Channel Blockers
Sodium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action